Informação sobre produto
- BSF 208075
- LU 208075
- Letairis
- Volibris,Ambrisentan
- (alphaS)-alpha-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl-benzenepropanoic Acid
- Benzenepropanoic acid
- alpha-[(4,6-dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl-
- (S)-
- (alphaS)-alpha-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenylbenzenepropanoic acid
- 3109.F
- Ver mais sinónimos
- GSK 1325760
- 4051.F
- (2S)-2-[(4,6-Dimethylpyrimidin-2-Yl)Oxy]-3-Methoxy-3,3-Diphenylpropanoic Acid
- (As)-A-[(4,6-Dimethyl-2-Pyrimidinyl)Oxy]--Methoxy--Phenylbenzenepropanoic Acid
- (αS)-α-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-β-methoxy-β-phenylbenzenepropanoic acid
- 2-(4,6-Dimethylpyrimidin-2-Yl)Oxy-3-Methoxy-3,3-Di(Phenyl)Propanoic Acid
- Benzenepropanoic acid, α-[(4,6-dimethyl-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-, (S)-
- Benzenepropanoic acid, α-[(4,6-dimethyl-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-, (αS)-
- Bsf 208075
- Bsf 208075,(+)-(2S)-2-[(4,6-Dimethylpyrimidin-2-Yl)Oxy]-3-Methoxy-3,3-Diphenylpropanoic Acid
- Lu 208075
- Volibris
Applications Nonpeptide endothelin ETA receptor antagonist. Antihypertensive.
References Riechers, H., et al.: J. Med. Chem., 39, 2123 (1996), Billman, G.E., et al.: Curr. Opin. Invest. Drugs, 3, 1483 (2002), Vatter, H., et al.: Clin. Neuropharmacol., 26, 73 (2003),
Propriedades químicas
Consulta técnica sobre: TR-A575860 Ambrisentan
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.